236 related articles for article (PubMed ID: 11855873)
1. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
Dizon DS; Sabbatini PJ; Aghajanian C; Hensley ML; Spriggs DR
Gynecol Oncol; 2002 Mar; 84(3):378-82. PubMed ID: 11855873
[TBL] [Abstract][Full Text] [Related]
2. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
3. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.
Callahan MB; Lachance JA; Stone RL; Kelsey J; Rice LW; Jazaeri AA
Am J Obstet Gynecol; 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PubMed ID: 17689649
[TBL] [Abstract][Full Text] [Related]
4. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
6. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
[TBL] [Abstract][Full Text] [Related]
7. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.
Gadducci A; Tana R; Teti G; Zanca G; Fanucchi A; Genazzani AR
Int J Gynecol Cancer; 2008; 18(4):615-20. PubMed ID: 18754135
[TBL] [Abstract][Full Text] [Related]
10. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
11. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
12. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin.
Enrique E; Malek T; Castelló JV; de Mateo JA
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):86. PubMed ID: 18254488
[No Abstract] [Full Text] [Related]
14. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.
Tamiya M; Kuhara H; Hirashima T; Kondo Y; Santo M; Morishita N; Suzuki H; Sasada S; Okamoto N; Kobayashi M; Kawase I
Anticancer Res; 2011 Dec; 31(12):4525-8. PubMed ID: 22199326
[TBL] [Abstract][Full Text] [Related]
16. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.
Greene DP; Ferriss JS; Jazaeri AA
Cancer Chemother Pharmacol; 2010 Jul; 66(2):265-7. PubMed ID: 19844714
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
[TBL] [Abstract][Full Text] [Related]
19. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases.
Libra M; Sorio R; Buonadonna A; Berretta M; Stefanovski P; Toffoli G; Mazzaglia G; Cordani N; Stivala F; Boiocchi M
Tumori; 2003; 89(3):311-3. PubMed ID: 12908789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
